BONESUPPORT, a supplier of injectable bone substitutes for orthopaedic trauma, bone infections and instrument augmentation related to orthopaedic surgery, announced the first patient outcomes data of CERAMENT™|G pertaining to an ongoing clinical trail in patients with osteomyelitis, as presented at The 4th Annual Oxford Bone Infection Conference. In the report, 41 patients treated with CERAMENT™|G had no recurrence of infection, no late wound leakage, no toxicity and no renal complications at a mean follow-up of nine months. Additionally, 78% of the patients demonstrated complete bone remodelling at six months.
CERAMENT™|G is the first injectable antibiotic eluting bone substitute indicated to promote and protect bone healing being jeopardized by infection.
“Local antibiotic management of osteomyelitis provides a much-needed treatment option for people who suffer from chronic bone infections,” said Mr Martin McNally, lead surgeon of the Bone Infection Unit at the Nuffield Orthopaedic Centre in Oxford. “We are pleased by early results and are optimistic that CERAMENT™|G offers the potential to improve health outcomes, lower healthcare costs and deliver a higher quality of life for patients suffering from this devastating disease.”
Osteomyelitis, or bone infection, is a $1.7 billion market where prolonged, long-term antibiotic therapy, multiple surgical interventions and the threat of amputation are the current standard of care. Rising prosthetic infections, diabetic ulcers, war injuries, sports injuries, and an increasing resistance to antibiotics contribute to this growing condition.
“The CERAMENT™ platform has a long-standing safety profile and we are pleased to see this once again confirmed in the CERAMENT™|G study,” said Lloyd Diamond, CEO of BONESUPPORT. “CERAMENT™|G is an important advancement in the treatment of bone infections and we are proud to be at the forefront of this advancement in care.”
